Real-world incidence and outcomes of immune-related adverse events in NSCLC patients

被引：1
|
作者：
Knox, A. [1 ]
Cloney, T. [1 ]
Janssen, H. [1 ]
Solomon, B. [1 ]
Alexander, M. [2 ]
John, T. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.629
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
551P
引用
收藏
页码：S1684 / S1684
页数：1
相关论文
共 50 条
  • [41] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
  • [42] Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC
    Sung, M.
    Zer, A.
    Walia, P.
    Khoja, L.
    Maganti, M.
    Labbe, C.
    Shepherd, F.
    Bradbury, P.
    Liu, G.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S929 - S929
  • [43] Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors
    Kottschade, Lisa A.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (03)
  • [44] Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors
    Lisa A. Kottschade
    Current Oncology Reports, 2018, 20
  • [45] Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
    Shimozaki, Keitaro
    Sukawa, Yasutaka
    Beppu, Noriko
    Kurihara, Isao
    Suzuki, Shigeaki
    Mizuno, Ryuichi
    Funakoshi, Takeru
    Ikemura, Shinnosuke
    Tsugaru, Kai
    Togasaki, Kazuhiro
    Kawasaki, Kenta
    Hirata, Kenro
    Hayashi, Hideyuki
    Hamamoto, Yasuo
    Takaishi, Hiromasa
    Kanai, Takanori
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4585 - 4593
  • [46] Immune-Related Adverse Events and their Association with Effectiveness of PD-1/PD-L1 Inhibitors in NSCLC: A Real-World Study from China
    Chen, X.
    Fang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S303 - S303
  • [47] Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
    Reynolds, Kerry L.
    Arora, Shaily
    Elayavilli, Ravikumar Komandur
    Louv, William C.
    Schaller, Teilo H.
    Khandelwal, Aakanksha
    Rothenberg, Mace
    Khozin, Sean
    Guidon, Amanda C.
    Dougan, Michael
    Zubiri, Leyre
    Petrillo, Laura
    Sise, Meghan E.
    Villani, Alexandra-Chloe
    Johnson, Douglas B.
    Rahma, Osama
    Sharon, Elad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [48] INCIDENCE OF MUSCULOSKELETAL AND SKIN IMMUNE-RELATED ADVERSE EVENTS WITH IMMUNE CHECKPOINT INHIBITORS
    Kim, J. H.
    Ng, J.
    Sanmugarajah, J.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 45 - 46
  • [49] Immune-Related Adverse Events in Patients with Lung Cancer
    Guilherme Sacchi de Camargo Correia
    Tanmayi Pai
    Shenduo Li
    Dana Connor
    Yujie Zhao
    Yanyan Lou
    Rami Manochakian
    Current Oncology Reports, 2023, 25 : 1259 - 1275
  • [50] Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
    Park, Benjamin C. C.
    Narayanan, Sathya
    Gavraldis, Alexander
    Ye, Fei
    Fan, Run
    Sullivan, Ryan J. J.
    Boland, Genevieve
    Reynolds, Kerry L.
    Balko, Justin M. M.
    Carlino, Matteo S. S.
    Long, Georgina V. V.
    Zubiri, Leyre
    Menzies, Alexander M. M.
    Johnson, Douglas B. B.
    ONCOIMMUNOLOGY, 2023, 12 (01):
12345